Logotipo del SMU


Uruguayan Medical Journal

ISSN: 1688-0390

Vol.31 - Nº 4 - Dic. 2015

Previous Art | Index | Next Art

Bone mineral density changes in patients who receive androgenic deprivation therapy for prostate cancer

Rev Med Urug 2015; 31: 249-258
Full text (spanish) |  Full text (spanish) (New windows, pdf) | Abstract


Introduction: prostate cancer is the most frequent malignant tumor in men in Uruguay. Androgenic deprivation therapy (ADT) is a valuable tool to treat this condition. In spite of it being highly effective, this treatment has several non-desirable effects, a reduction in bone mineral density being among them.

Material: we conducted a longitudinal, observational and prospective study whose objective was to determine whether there is a reduction in bone mineral density in patients who receive ADT for prostate cancer. Patients who were carriers of prostate cancer undergoing any stage who would start their ADT treatment at the Oncology Unit of the University Hospital of Montevideo from September 2012 through August 2013 were included in the study. All of them underwent a bone densitometry prior to the initiation of ADT (BD1) treatment and it was repeated six months after they received the first dose of hormone treatment (BD2). Measurements of bone density were compared for every region analysed in g/ cm2 in BD1 versus BD2.

Results: Ten patients with an average age of 77 years old were followed-up. A significant reduction in bone mineral density was observed in the L3-L4 spinal segment (L3: 1.268 g/cm2 at 1.225 g/cm2 p=0.01; L4: 1.247g/cm2 at 1.227g/cm2 p=0.005), whereas in the other points assessed (L1, L2, femoral neck and total hip) there was a reduction as well, although it did not represent any statistical significance.

Conclusions: we confirmed ADT reduces the bone mineral density in lumbar vertebrae L3 and L4 in a relatively short time (six minths). This negative effect needs to be timely assessed, identified and prevented to avoid greater complications.